SEARCH · Search NASA
Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
The contribution of the vestibular system to motion sickness experience is studied by means of an attempt to determine the relationship between five subjective tests of vestibular function and reports of motion sickness experiences by pilots and nonpilots. The experimental procedure is described and the obtained results are discussed.
AFT (Autogenic Feedback Training) involves practicing a series of mental exercises to speed up or slow down the control of autonomic activity. This produces a reduced tendency for autonomic activity levels to diverge from baseline (at rest) under stressful motion-sickness-inducing conditions. Subjects conditions. Subjects engaged in applying AFT exercises are required to closely monitor their own bodily sensations during motion-sickness-eliciting tests. These tests include the Coriolis Sickness Susceptibility Index (CSSI), which consists of sitting a subject into a rotating chair that moves at various speeds while a visual background turns at differing speeds and directions, and the Vertical Acceleration Rotation Device (VARD) test, which involves the placing of a subject in a drum that moves in an upward and downward motion until he or she is sick, while simultaneously monitoring the subject's vital signs. These tests provide investigators with evidence of slight changes in autonomic activities such as increases in heart rate, skin temperature, and sweat. All of these symptoms occur in subjects that experience bodily weakness or discomfort with the onset of motion sickness.
Prolonged exposure to an inappropriate vestibulo-ocular reflex (VOR) will usually lead to motion sickness, and it has been predicted on theoretical grounds that VOR gain may be decreased in weightlessness. While experiments during parabolic flight in aircraft tend to confirm this prediction, experiments during orbital spaceflight have led to apparently contradictory results. It is suggested that VOR gain is reduced initially, but that rapid compensatory mechanisms restore it to normal within minutes of reaching weightlessness. However, even though this process may lead to the rapid return of functionally normal gaze stability, it may not protect against the development of motion sickness.
Motion sickness susceptibility of four normal subjects was measured in terms of duration of exposure necessary to evoke moderate malaise (MIIA) as a function of velocity in a chair rotated about a central axis tilted 10 deg with respect to gravitational upright. The subjects had little or no susceptibility to this type of rotation at 2.5 and 5.0 rpm, but with further increases in rate, the MIIA endpoint was always reached and with ever shorter test durations. Minimal provocative periods for all subjects were found at 15 or 20 rpm. Higher rotational rates dramatically reversed the vestibular stressor effect, and the subjects as a group tended to reach a plateau of relatively low susceptibility at 40 and 45 rpm. At these higher velocities, furthermore, the subjects essentially lost their sensation of being tilted off vertical. In the second half of the study, the effect of tilt angle was varied while the rotation rate was maintained at a constant 17.5 rpm. Two subjects were completely resistant to symptoms of motion sickness when rotated at 2.5 deg off vertical; with greater off-vertical angles, the susceptibility of all subjects increased sharply at first, then tapered off in a manner reflecting a Fechnerian function.
Antimotion sickness drugs and placebos effect on altering motion sickness susceptibility in Skyraider aircraft aerobatics and Slow Rotation Room dial test
Susceptibility to acute motion sickness in blind persons
This study evaluated the efficacy of pharmacological doses of phosphatidylcholine (lecithin) in the modulation of motion sickness induced by exposure to coriolis stimulation in a rotating chair. Subjects received daily dietary supplements of 25 grams of lecithin (90 percent phosphatidylcholine) and were tested for their susceptibility to motion sickness after 4 h, 2 d, and 21 d. A small but statistically significant increase in susceptibility (+15 percent) was noted 4 h after supplemental phosphatidylcholine, with four of nine subjects demonstrating a marked increase in susceptibility. This finding was attributed to choline's stimulatory action on cholinergic systems, an action which opposes that of the classical antimotion sickness drug scopolamine. Chronic lecithin loading revealed a trend towards reduced susceptibility, possibly indicating the occurrence of adaptive mechanisms such as receptor down-regulation. Withdrawal from lecithin loading, perhaps coupled with anticholinergic treatment, might prove to be a potent prophylactic regimen and ought to be tested.
Efficacy of pharmacological preparation in combating motion sickness of air transport passengers
The one-equation and the two-equation logistic models were used to predict subjects' susceptibility to motion sickness in KC-135 parabolic flights using data from other ground-based motion sickness tests. The results show that the logistic models correctly predicted substantially more cases (an average of 13 percent) in the data subset used for model building. Overall, the logistic models ranged from 53 to 65 percent predictions of the three endpoint parameters, whereas the Bayes linear discriminant procedure ranged from 48 to 65 percent correct for the cross validation sample.
Previous experiments with moving platform posturography have shown that different people have varying abilities to resolve conflicts among vestibular, visual, and proprioceptive sensory signals used to control upright posture. In particular, there is one class of subjects with a vestibular disorder known as benign paroxysmal positional vertigo (BPPV) who often are particularly sensitive to inaccurate visual information. That is, they will use visual sensory information for the control of their posture even when that visual information is inaccurate and is in conflict with accurate proprioceptive and vestibular sensory signals. BPPV has been associated with disorders of both posterior semicircular canal function and possibly otolith function. The present proposal hopes to take advantage of the similarities between the space motion sickness problem and the sensory orientation reference selection problems associated with the BPPV syndrome. These similarities include both etiology related to abnormal vertical canal-otolith function, and motion sickness initiating events provoked by pitch and roll head movements. The objectives of this proposal are to explore and quantify the orientation reference selection abilities of subjects and the relation of this selection to motion sickness in humans.
Simulator training for motion sickness suppression in prolonged space flight
To make comparisons with experimental motion sickness susceptibility in Skylab missions, subjects were tested during free fall in parabolic flight and in ground-based simulation tests. They were rotated at 30 rpm in a rotating litter chair (RLC) with head fixed, head swiveling left-to-right, or with 90 degree forward and return head and body movements. Stressful accelerations similar to those in the Skylab RLC were generated only in the tests aloft, where subjects who made 'forward and return' movements (generating cross-coupled angular accelerations) were substantially more prone to motion sickness than those with either head fixed or head swiveling left-to-right. However, with head swiveling, susceptibility was slightly higher in the laboratory than aloft.
This report concerns the use of intramuscular injections of scopolamine, promethazine, and dramamine to treat severely motion sick individuals participating in parabolic flight experiments. The findings indicate that a majority of individuals received benefit from 50-mg injections of promethazine or 0.5 mg-injections of scopolamine. By contrast, 50-mg injections of dramamine and 25-mg injections of promethazine were nonbeneficial. The use of antimotion drug injections for treating space motion sickness is discussed.
This article summarizes a variety of newly published findings obtained by the Neuroscience Laboratory, Johnson Space Center, and attempts to place this work within a historical framework of previous results on posture, locomotion, motion sickness, and perceptual responses that have been observed in conjunction with space flight. In this context, we have taken the view that correct transduction and integration of signals from all sensory systems is essential to maintaining stable vision, postural and locomotor control, and eye-hand coordination as components of spatial orientation. The plasticity of the human central nervous system allows individuals to adapt to altered stimulus conditions encountered in a microgravity environment. However, until some level of adaptation is achieved, astronauts and cosmonauts often experience space motion sickness, disturbances in motion control and eye-hand coordination, unstable vision, and illusory motion of the self, the visual scene, or both. Many of the same types of disturbances encountered in space flight reappear immediately after crew members return to earth. The magnitude of these neurosensory, sensory-motor and perceptual disturbances, and the time needed to recover from them, tend to vary as a function of mission duration and the space travelers prior experience with the stimulus rearrangement of space flight. To adequately chart the development of neurosensory changes associated with space flight, we recommend development of enhanced eye movement systems and body position measurement. We also advocate the use of a human small radius centrifuge as both a research tool and as a means of providing on-orbit countermeasures that will lessen the impact of living for long periods of time with out exposure to altering gravito-inertial forces. Copyright 1998 Elsevier Science B.V.
Drugs altering susceptibility to motion sickness in aerobatics and slow rotation room
The new drug, AHR 5645B, together with other drugs was evaluated in tests, conducted with eight male subjects, concerning its ability to prevent motion sickness. It was found that AHR 5645B, used in doses of 20, 50, and 100 mg, was not efficacious in preventing experimental motion sickness. A combination of 50 mg meclizine and 25 mg ephedrine sulfate produced the best results. Favorable results were also obtained with a combination of 12.5 mg promethazine hydrochloride and 12.5 mg ephedrine sulfate. The findings in the reported experiment point to the difficulty of identifying a highly efficacious antimotion sickness drug for everyone.
Motion sickness symptomology of labyrinthine defective and normal human subjects during zero gravity maneuvers
Diagnostic criteria for grading severity of acute motion sickness